Featured studies include only those currently recruiting participants. They are listed according to the date they were added to the ClinicalTrials.gov registry, with the most recent studies appearing first.
- Daily Intranasal Oxytocin for Childhood-Onset Schizophrenia.
Interventional study. Background: - Oxytocin is a chemical that the brain normally produces. Ages 10 and over. Location in Bethesda, MD.
- Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography.
Evaluation study. Background: - Some illnesses, such as schizophrenia, have effects on brain cells called dopamine receptors, which are required for normal brain function. Ages 18-90. Location in Bethesda, MD.
- Transcranial Direct Current Brain Stimulation to Treat Patients With Childhood-Onset Schizophrenia.
Interventional study. This study will test whether transcranial direct current stimulation (TDCS) can be used safely in children with schizophrenia and if it can improve memory and attention span or auditory hallucinations in these children, at least temporarily. Ages 10 and over. Location in Bethesda, MD.
- Using D-cycloserine to Enhance the Benefits of Cognitive Behavioral Therapy for Schizophrenia.
Interventional study. This study will examine whether pretreatment with D-cycloserine before cognitive behavioral therapy can reduce impairments still present in people with stable cases of schizophrenia as well as determine which traits make schizophrenics most likely to respond to D-cycloserine treatment. Ages 18-65. Location in Boston, MA.
- A Self-Management Program for Adults With Both Schizophrenia and a Co-Occurring Medical Condition.
Interventional study. This study will develop and evaluate the effectiveness of a self-management program for adults living with both schizophrenia and a co-occurring medical condition. Ages 18-64. Location in Baltimore, MD.
- Effectiveness of Tropisetron Plus Risperidone for Improving Cognitive and Perceptual Disturbances in Schizophrenia.
Interventional study. This study will determine the effectiveness of tropisetron plus risperidone in improving cognitive and perceptual disturbances and symptoms in Chinese people with schizophrenia. Ages 18-64. Locations in Houston, TX; Beijing, China.
- Determining Metabolic Effects of Valproate and Antipsychotic Therapy.
Interventional study. This study will determine the metabolic processes responsible for high levels of blood glucose, metabolism disorders, and weight gain in people with schizophrenia who have been treated with antipsychotic medications in combination with valproate. Ages 18-60. Location in St. Louis, MO.
- Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia.
Interventional study. This study will assess the effectiveness of pimozide in enhancing the effects of clozapine in the treatment of schizophrenia. Ages 18-65. Locations in New York, NY; W. Brentwood, NY.
- Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia.
Interventional study. This study will examine the effects of ondansetron on auditory nerve activity in people with schizophrenia who are being treated with new antipsychotics. Ages 18-55. Location in Denver, CO.
- Effects of Modafinil on Brain Function in Patients With Schizophrenia.
Interventional study. This study will evaluate whether modafinil improves cognition in patients with schizophrenia and healthy volunteers. Ages 18-50. Location in Bethesda, MD.
- Screening for Childhood-Onset Psychotic Disorders.
Evaluation study. The purpose of this study is to screen and evaluate children with psychotic disorders to establish or confirm their diagnosis and to collect data about their condition. Ages 5 and over. Location in Bethesda, MD.
- Clinical Trial of Tolcapone for Cognition in Schizophrenia.
Interventional study. This study will evaluate whether Atomoxetine improves cognition in healthy volunteers as well as patients with schizophrenia. Ages 18-50. Location in Bethesda, MD.
- Inpatient Evaluation of Adults With Schizophrenia.
Evaluation study. The purpose of this study is to understand the biologic basis of schizophrenia and to determine which symptoms are related to the illness itself and which are related to medications used to treat the illness. Ages 18 and over. Location in Bethesda, MD.
- Studies of Frontal Lobe Brain Functioning in Schizophrenia.
Evaluation study. The purpose of this study is to use brain imaging technology to investigate the role of the frontal lobe of the brain in the thinking of individuals with schizophrenia and other neuropsychiatric disorders and healthy volunteers. Ages 18-90. Location in Bethesda, MD.
- Brain Tissue Collection for Neuropathological Studies.
Evaluation study. The purpose of this study is to collect and study the brain tissue of deceased individuals to learn more about the nervous system and mental disorders. Locations in Washington, DC; Bethesda, MD; Fairfax, VA.
- Evaluation of the Genetics of Bipolar Disorder.
Evaluation study. This study looks to identify genes that may affect a person's chances of developing bipolar disorder (BP) and related conditions. Ages 18 and over. Location in Bethesda, MD.
- Genetic Study of Schizophrenia.
Evaluation study. This large ongoing study at NIMH investigates the neurobiology of schizophrenia by identifying susceptibility genes, evaluating their impact on brain function to better understand how to treat and prevent this illness. Ages 18 and over. Location in Bethesda, MD.
- Evaluating Genetic Risk Factors for Childhood-Onset Schizophrenia.
Evaluation study. A study of children and adolescents (current N=100) with very early onset by age 12 (COS) of DSM-III-R defined schizophrenia with (97-M-0126) is examining the clinical, neurobiological, early neurodevelopmental, genetic, and clinical drug response characteristics of these cases. Ages 6 and over. Location in Bethesda, MD.